Novel treatment (new drug/intervention; established drug/procedure in new situation)
A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib
1 Royal Marsden NHS Foundation Trust, Medical Oncology, London, SW3 6JJ, UK
2 Imperial College London, Renal Section, London, W12 ONN, UK
3 Willam Harvey Research Institute, Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, EC1M 6BQ, UK
4 Cambridge University, Cambridge, CB2 OQQ, UK
Correspondence to:
marktuthill{at}doctors.org.uk
We report a patient who initially presented with an abdominal paraganglioma and subsequently metastatic papillary cell renal cancer. Genetic analysis revealed a 141 G>A (exon 2) Trp47X mutation within the succinate dehydrogenase B gene. Treatment with the novel multi-targeted tyrosine kinase inhibitor sunitinib resulted in a sustained partial response and reduced the level of the angiogenic marker PIGF.
Trial registration number: a6181037
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
eLetters:
Read all eLetters
- Loss of heterozygosity in SDHB locus on chromosome 1 in a subject with a metastatic papillary type I
- Dr. Umasuthan Srirangalingam, et al.
- BMJ Case Reports Online, 1 May 2009 [Full text]
- Full Text
- Submit a response
- Read responses to this article
- Alert me when this article is cited
- Alert me when eLetters are posted
- Alert me if a correction is posted
Services
- Email this link to a friend
- Similar articles in this journal
- Add article to my folders
- Download to citation manager
- Request Permissions
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with
Register for free content
The full text of all Editor's Choice articles and summaries of every article are free without registration
The full text of Images in ... articles are free to registered users
Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource
Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog
